A phase II clinical trial evaluated the safety and efficacy of radotinib for patients with chronic phase chronic myeloid leukemia (CP-CML) with resistance and/or intolerance to other BCR-ABL1 TKIs and concluded that radotinib was well tolerated and effective. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.